Design smarter trials with
biomarker intelligence.
The Alzheimer's Disease Biomarker Observatory curates cutting-edge biomarker research and structured evidence from thousands of past and ongoing clinical trials — helping sponsors choose the right biomarkers, endpoints, and strategies for their programs.
Match biomarkers to your mechanism, population, and endpoints using a curated ontology grounded in the latest research.
See how biomarkers have been used across the AD pipeline — by phase, mechanism, and specimen — to inform your design.
Stay aligned with a landscape that updates continuously as new trials, readouts, and biomarker evidence emerge.
What the Observatory provides
A growing suite of AI tools and curated datasets, built on continuously annotated clinical-trial data. Some capabilities are available today; others are actively in development.
A structured tree of Alzheimer's biomarkers organized by AT(N) & CADRO framework, modality (fluid, imaging, digital), and specimen type — continuously curated by our research team.
Dual-LLM extraction plus PubMedBERT/BioLinkBERT detection and an ontology-aware string matcher pull biomarkers out of trial eligibility and outcome text at scale.
A structured, expert-annotated view of how biomarkers are used across the AD pipeline — the “natural counterpart to the clinical trial report.”
Pipeline pivots by phase, mechanism, and modality, plus longitudinal dynamics showing how the landscape shifts year over year.
Field-level change detection across ClinicalTrials.gov — status, outcomes, eligibility, and contacts — so the evidence base stays current.
Data-driven recommendations to help match candidate biomarkers to a trial's mechanism, phase, and population.
Benchmark a proposed design against comparable prior trials — biomarker choices, endpoints, and outcomes.
Expansion to other neurodegenerative diseases so cross-indication biomarker strategies can be explored.
Tailored reports and API access to bring Observatory data directly into your own research workflows.
Notifications when new biomarker evidence or competitive-landscape changes are relevant to your program.
Link biomarkers to therapeutic mechanisms and targets across the pipeline for deeper program context.
Every layer is reviewed by the UNLV Chambers-Grundy Center research team — curation, not just aggregation.
Source: Cummings et al. (2025), Alzheimer's & Dementia: TRCI. The Observatory turns figures like these into structured, queryable biomarker intelligence.
Working with us
We partner with trial sponsors and industry research teams to bring curated biomarker evidence to program decisions.
Tell us about your program — indication, mechanism, and where you are in development.
We assemble relevant biomarker research and trial precedents from the Observatory.
Use the insights to inform biomarker selection, endpoints, and trial strategy.
Bring biomarker intelligence to your next trial
Let's talk about how the Observatory can support your program.
Get in touch